Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-26
2010-12-14
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07851485
ABSTRACT:
Disclosed is a therapeutic agent for neuropathic pain having an excellent therapeutic effect on neuropathic pain which is a intractable disease. More specifically, disclosed are a therapeutic agent for neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist (particularly PK 11195) as the active ingredient; a pharmaceutical composition for the treatment of neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist as the active ingredient; a method for the treatment of neuropathic pain using a peripheral benzodiazepine receptor antagonist; and others.
REFERENCES:
patent: 2008/0194620 (2008-08-01), Besne et al.
patent: 2002-516279 (2002-06-01), None
patent: WO 99/49316 (1999-09-01), None
patent: WO 99/61024 (1999-12-01), None
patent: WO 00/37086 (2000-06-01), None
Supplementary European Search Report dated Dec. 7, 2009, in corresponding EP 06732484.2, 8 pages.
Galiegue et al., “The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target,” Current Medicinal Chemistry, 2003, 10:1563-1572.
Hempenstall et al., “Current treatment options in neuropathic pain,” Current Opinion in Investigational Drugs, 2002, 3(3):441-448.
Kontinen et al., “Effects of midazolam in the spinal nerve ligation model of neuropathic pain in rats,” Pain, 2000, 85:425-431.
Dalbo et al., “Antinociceptive Effects of Peripheral Benzodiazepine Receptors,” Pharmacology, 2004, 70(4):188-94.
Database BIOSIS on STN, BIOSIS (Philadelphia, PA, USA), DN: PREV200000147669 & Sloan, J.W. et al., Effect of chronic diazepam (DZ) treatment, and flumazenil (FLU)—and PK 11195 (PK)-induced withdrawal on the pain threshold in femal rats, Society for Neuroscience Abstracts, 1999, vol. 25, No. 1-2, p. 1948 (abstract, two pages).
Karchewski et al., “Axonal injury-dependent induction of the peripheral benzodiazepine receptor in small-diameter adult rat primary sensory neurons,” European Journal of Neuroscience, 2004, 20(3):671-83.
Rady et al., “Confluence of Antianalgesic Action of Diverse Agents through Brain Interleukin1βin Mice,” J. Pharmacol. Exp. Ther., 2001, 299(2):659-665.
Xiao et al., “Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain,” Proc. Natl. Acad. Sci., Jun. 11, 2002, 99(12):8360-8365.
Foley & Lardner LLP
Henley, III Raymond J
Japan Science and Technology Agency
National University Corporation, Tokyo Medical and Dental Univer
LandOfFree
Therapeutic agent for neuropathic pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for neuropathic pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for neuropathic pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220504